The U.S. Food and Drug Administration on June 12 approved a Sanofi injection intended to slow the loss of the body's own insulin production in children aged 8 to 17 recently diagnosed with stage 3 type 1 diabetes.
The treatment aims to preserve endogenous insulin production in the early stages of the disease. The FDA announced the decision on Friday; the report was filed by Reuters.
The U.S. Food and Drug Administration on June 12 approved a Sanofi injection designed to slow the loss of the body's own insulin production in children aged 8 to 17 who were recently diagnosed with stage 3 type 1 diabetes, the agency said on Friday.
Target Population: Children aged 8 to 17 years recently diagnosed with stage 3 type 1 diabetes.
Purpose of Treatment: The injection is intended to slow the decline of endogenous insulin production, helping preserve the patient's remaining beta-cell function after diagnosis.
The FDA announcement was made public on Friday, June 12. The report was filed by Kunal Das in Bengaluru for Reuters.
This approval provides a new therapeutic option aimed at modifying early disease progression in pediatric patients with stage 3 type 1 diabetes. Healthcare providers and families should consult guidance from specialists and the FDA labeling for details on use, eligibility and potential risks.
Help us improve.
